AfioneS.A., ConradC.K., KearnsW.G., et al. (1996). In vivo model of adeno-associated virus vector persistence and rescue. J Virol, 70, 3235–3241.
2.
AmalfitanoA., Mcvie-WylieA.J., HuH., et al. (1999). Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A, 96, 8861–8866.
3.
AngeliniC., and EngelA.G. (1973). Subcellular distribution of acid and neutral alpha-glucosidases in normal, acid maltase deficient, and myophosphorylase deficient human skeletal muscle. Arch Biochem Biophys, 156, 350–355.
4.
AskanasV., EngelW.K., DimauroS., et al. (1976). Adult-onset acid maltase deficiency. Morphologic and biochemical abnormalities reproduced in in cultured muscle. N Engl J Med, 294, 573–578.
5.
ATS/ERS. (2002). ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med, 166, 518–624.
6.
BaudhuinP., HersH.G., and LoebH. (1964). An electron microscopic and biochemical study of type II glycogenosis. Lab Invest, 13, 1139–1152.
7.
BernsK.I., and LindenR.M. (1995). The cryptic life style of adeno-associated virus. Bioessays, 17, 237–245.
8.
BlacklowN.R., HogganM.D., and RoweW.P. (1968). Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst, 40, 319–327.
9.
BoonA.J., AlsharifK.I., HarperC.M., and SmithJ. (2008). Ultrasound-guided needle EMG of the diaphragm: technique description and case report. Muscle Nerve, 38, 1623–1626.
10.
BrantlyM.L., ChulayJ.D., WangL., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A, 106, 16363–16368.
11.
BrochardL., and ThilleA.W. (2009). What is the proper approach to liberating the weak from mechanical ventilation?. Crit Care Med, 37, S410–S415.
ChaoH., LiuY., RabinowitzJ., et al. (2000a). Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther, 2, 619–623.
14.
ChaoH., MaoL., BruceA.T., and WalshC.E. (2000b). Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood, 95, 1594–1599.
15.
ChaoH., MonahanP.E., LiuY., SamulskiR.J., et al. (2001). Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther, 4, 217–222.
16.
ChioriniJ.A., YangL., LiuY., SaferB., et al. (1997). Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol, 71, 6823–6833.
17.
ChioriniJ.A., AfioneS., and KotinR.M. (1999). Adeno-associated virus (AAV) type 5 Rep protein cleaves a unique terminal resolution site compared with other AAV serotypes. J Virol, 73, 4293–4298.
18.
ClarkK.R., VoulgaropoulouF., FraleyD.M., and JohnsonP.R. (1995). Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther, 6, 1329–1341.
19.
ClarkK.R., SferraT.J., and JohnsonP.R. (1997). Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther, 8, 659–669.
20.
CoastJ.R., JensenR.A., CassidyS.S., RamanathanM., et al. (1988). Cardiac output and O2 consumption during inspiratory threshold loaded breathing. J Appl Physiol, 64, 1624–1628.
21.
ConwayJ.E., RhysC.M., ZolotukhinI., ZolotukhinS., et al. (1999). High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther, 6, 986–993.
22.
De BarsyT., JacqueminP., Van HoofF., and HersH.G. (1973). Enzyme replacement in Pompe disease: an attempt with purified human acid alpha-glucosidase. Birth Defects Orig Artic Ser, 9, 184–190.
23.
DeRuisseauL.R., FullerD.D., QiuK., DeRuisseauK.C., et al. (2009). Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A, 106, 9419–9424.
24.
DoucetM., DebigareR., JoanisseD.R., CoteC., et al. (2004). Adaptation of the diaphragm and the vastus lateralis in mild-to-moderate COPD. Eur Respir J, 24, 971–979.
25.
DronkersJ., VeldmanA., HobergE., Van Der WaalC., et al. (2008). Prevention of pulmonary complications after upper abdominal surgery by preoperative intensive inspiratory muscle training: a randomized controlled pilot study. Clin Rehabil, 22, 134–142.
26.
DuringM.J., SamulskiR.J., ElsworthJ.D., KaplittM.G., et al. (1998). In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther, 5, 820–827.
27.
FerrariF.K., SamulskiT., ShenkT., and SamulskiR.J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol, 70, 3227–3234.
28.
FisherK.J., JoossK., AlstonJ., YangY., et al. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med, 3, 306–312.
29.
FlanneryJ.G., ZolotukhinS., VaqueroM.I., LavailM.M., et al. (1997). Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A, 94, 6916–6921.
30.
FlotteT.R., and CarterB.J. (1995). Adeno-associated virus vectors for gene therapy. Gene Ther, 2, 357–362.
31.
FlotteT.R., AfioneS.A., ConradC., McgrathS.A., et al. (1993). Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A, 90, 10613–10617.
32.
FraitesT.J.Jr., SchleissingM.R., ShanelyR.A., WalterG.A., et al. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther, 5, 571–578.
33.
FukudaT., EwanL., BauerM., MattalianoR.J., et al. (2006). Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol, 59, 700–708.
34.
GambettiP., DimauroS., and BakerL. (1971). Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol, 30, 412–430.
35.
GaoG.P., QuG., FaustL.Z., EngdahlR.K., et al. (1998). High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther, 9, 2353–2362.
36.
GaoG.P., AlviraM.R., WangL., CalcedoR., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A, 99, 11854–11859.
37.
GriegerJ.C., and SamulskiR.J. (2005). Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol, 99, 119–145.
38.
GriffinJ.L. (1984). Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol, 45, 23–36.
39.
HalbertC.L., RutledgeE.A., AllenJ.M., RussellD.W., et al. (2000). Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol, 74, 1524–1532.
40.
HauswirthW.W., LiQ., RaislerB., TimmersA.M., et al. (2004). Range of retinal disease potentially treatable by AAV-vectored gene therapy. Novartis Found Symp, 255, 179–188; discussion 188–194.
41.
HermansG., AgtenA., TestelmansD., DecramerM., et al. (2010). Increased duration of mechanical ventilation is associated with decreased diaphragmatic force: a prospective observational study. Crit Care, 14, R127.
42.
HermonatP.L., and MuzyczkaN. (1984). Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A, 81, 6466–6470.
43.
HermonatP.L., LabowM.A., WrightR., BernsK.I., et al. (1984). Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol, 51, 329–339.
Hirschorn RarA.J. (2000). Glycogen Storage Disase II: Acid-alpha glucosidase (acid maltase) deficiency. In Metabolic Basis of Inherited Disease. ScrieverC.R., SlyW.S., and ValleD., eds. (McGraw Hill, New York) pp. 3389–3420.
46.
HoefslootL.H., WillemsenR., KroosM.A., Hoogeveen-WesterveldM., et al. (1990). Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J, 272, 485–492.
47.
HuangC.H., MartinA.D., and DavenportP.W. (2003). Effect of inspiratory muscle strength training on inspiratory motor drive and RREP early peak components. J Appl Physiol, 94, 462–468.
48.
HuangC.H., MartinA.D., and DavenportP.W. (2009). Effects of inspiratory strength training on the detection of inspiratory loads. Appl Psychophysiol Biofeedback, 34, 17–26.
49.
HuangT.T., DeoghareH.V., SmithB.K., BeaverT.M., et al. (2011). Gene expression changes in the human diaphragm after cardiothoracic surgery. J Thorac Cardiovasc Surg, 142, 1214–1222, 1222 e1–20.
50.
HudgsonP., and FulthorpeJ.J. (1975). The pathology of type II skeletal muscle glycogenosis. A light and electron-microscopic study. J Pathol, 116, 139–147.
51.
HulzebosE.H., HeldersP.J., FavieN.J., De BieR.A., et al. (2006). Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA, 296, 1851–1857.
52.
HussainS.N., MofarrahiM., SigalaI., KimH.C., et al. (2010). Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy. Am J Respir Crit Care Med, 182, 1377–1386.
53.
ImD.S., and MuzyczkaN. (1989). Factors that bind to adeno-associated virus terminal repeats. J Virol, 63, 3095–3104.
54.
IsaacsH., SavageN., BadenhorstM., and WhistlerT. (1986). Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures. J Neurol Neurosurg Psychiatry, 49, 1011–1018.
55.
JaberS., PetrofB.J., JungB., ChanquesG., et al. (2011). Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am J Respir Crit Care Med, 183, 364–371.
56.
KaludovN., BrownK.E., WaltersR.W., ZabnerJ., et al. (2001). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol, 75, 6884–6893.
57.
KellermanB.A., MartinA.D., and DavenportP.W. (2000). Inspiratory strengthening effect on resistive load detection and magnitude estimation. Med Sci Sports Exerc, 32, 1859–1867.
58.
KesslerP.D., PodsakoffG.M., ChenX., McquistonS.A., et al. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A, 93, 14082–14087.
59.
KishnaniP.S., CorzoD., NicolinoM., ByrneB., et al. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology, 68, 99–109.
60.
KniselyA.S., LealS.M., and SingerD.B. (1988). Abnormalities of diaphragmatic muscle in neonates with ventilated lungs. J Pediatr, 113, 1074–1077.
61.
KoeberlD.D., AlexanderI.E., HalbertC.L., RussellD.W., et al. (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A, 94, 1426–1431.
62.
KotinR.M. (1994). Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther, 5, 793–801.
63.
KotinR.M., SiniscalcoM., SamulskiR.J., ZhuX.D., et al. (1990). Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A, 87, 2211–2215.
64.
KurachekS.C., NewthC.J., QuasneyM.W., RiceT., et al. (2003). Extubation failure in pediatric intensive care: a multiple-center study of risk factors and outcomes. Crit Care Med, 31, 2657–2664.
65.
LarsonP.J., and HighK.A. (2001). Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle. Adv Exp Med Biol, 489, 45–57.
66.
LevineS., KaiserL., LeferovichJ., and TikunovB. (1997). Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med, 337, 1799–1806.
67.
LevineS., GregoryC., NguyenT., ShragerJ., et al. (2002). Bioenergetic adaptation of individual human diaphragmatic myofibers to severe COPD. J Appl Physiol, 92, 1205–1213.
68.
LevineS., NguyenT., TaylorN., FrisciaM.E., et al. (2008). Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med, 358, 1327–1335.
69.
LiJ., SamulskiR.J., and XiaoX. (1997). Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol, 71, 5236–5243.
70.
LindsayD.C., LovegroveC.A., DunnM.J., BennettJ.G., et al. (1996). Histological abnormalities of muscle from limb, thorax and diaphragm in chronic heart failure. Eur Heart J, 17, 1239–1250.
71.
MacgowanN.A., EvansK.G., RoadJ.D., and ReidW.D. (2001). Diaphragm injury in individuals with airflow obstruction. Am J Respir Crit Care Med, 163, 1654–1659.
72.
MahC., FraitesT.J.Jr., CresawnK.O., ZolotukhinI., et al. (2004). A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol Ther, 9, 458–463.
73.
MahC., CresawnK.O., FraitesT.J.Jr., PacakC.A., et al. (2005). Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther, 12, 1405–1409.
74.
MahC., PacakC.A., CresawnK.O., DeruisseauL.R., et al. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther, 15, 501–507.
75.
MahC.S., FalkD.J., GermainS.A., KelleyJ.S., et al. (2010). Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther, 18, 502–510.
76.
MancallE.L., AponteG.E., and BerryR.G. (1965). Pompe's Disease (Diffuse Glycogenosis) with Neuronal Storage. J Neuropathol Exp Neurol, 24, 85–96.
77.
MandelR.J., and BurgerC. (2004). Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr Opin Mol Ther, 6, 482–490.
78.
MandelR.J., SprattS.K., SnyderR.O., LeffS.E. (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A, 94, 14083–14088.
79.
MartinA.D., DavenportP.D., FranceschiA.C., HarmanE. (2002). Use of inspiratory muscle strength training to facilitate ventilator weaning: a series of 10 consecutive patients. Chest, 122, 192–196.
80.
MatsushitaT., ElligerS., ElligerC., PodsakoffG., et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther, 5, 938–945.
81.
MckusickV. (1996). 232300 Glycogen Storage Disease II. In OMIM.
82.
MendelsonE., TrempeJ.P., and CarterB.J. (1986). Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide. J Virol, 60, 823–832.
83.
MercadierJ.J., SchwartzK., SchiaffinoS., WisnewskyC., et al. (1998). Myosin heavy chain gene expression changes in the diaphragm of patients with chronic lung hyperinflation. Am J Physiol, 274, L527–534.
84.
MoufarrejN.A., and BertoriniT.E. (1993). Respiratory insufficiency in adult-type acid maltase deficiency. South Med J, 86, 560–567.
85.
MuzyczkaN. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol, 158, 97–129.
86.
MuzyczkaN., SamulskiR.J., HermonatP., SrivastavaA., et al. (1984). The genetics of adeno-associated virus. Adv Exp Med Biol, 179, 151–161.
87.
NakaiH., YantS.R., StormT.A., FuessS., et al. (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol, 75, 6969–6976.
88.
NguyenT., RubinsteinN.A., VijayasarathyC., RomeL.C., et al. (2005). Effect of chronic obstructive pulmonary disease on calcium pump ATPase expression in human diaphragm. J Appl Physiol, 98, 2004–2010.
89.
NicolinoM.P., PuechJ.P., KremerE.J., ReuserA.J., et al. (1998). Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation. Hum Mol Genet, 7, 1695–1702.
90.
NicolinoM., ByrneB., WraithJ.E., LeslieN., et al. (2009). Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med, 11, 210–219.
91.
Orozco-LeviM., GeaJ., LloretaJ.L., FelezM., et al. (1999). Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J, 13, 371–378.
92.
Orozco-LeviM., LloretaJ., MinguellaJ., SerranoS., et al. (2001). Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164, 1734–1739.
93.
OttenheijmC.A., HeunksL.M., and DekhuijzenP.N. (2007). Diaphragm muscle fiber dysfunction in chronic obstructive pulmonary disease: toward a pathophysiological concept. Am J Respir Crit Care Med, 175, 1233–1240.
94.
PacakC.A., MahC.S., ThattaliyathB.D., ConlonT.J., et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res, 99, e3–9.
95.
PaulyD.F., JohnsD.C., MatelisL.A., LawrenceJ.H., et al. (1998). Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther, 5, 473–480.
96.
PaulyD.F., FraitesT.J., TomaC., BayesH.S., et al. (2001). Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease. Hum Gene Ther, 12, 527–538.
97.
PeelA.L., and KleinR.L. (2000). Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods, 98, 95–104.
98.
PonnazhaganS., EriksonD., KearnsW.G., ZhouS.Z., et al. (1997). Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther, 8, 275–284.
99.
PowersS.K., KavazisA.N., and LevineS. (2009). Prolonged mechanical ventilation alters diaphragmatic structure and function. Crit Care Med, 37, S347–S353.
100.
QingK., MahC., HansenJ., ZhouS., et al. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med, 5, 71–77.
101.
RabenN., PlotzP., and ByrneB.J. (2002). Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med, 2, 145–166.
102.
Ramirez-SarmientoA., Orozco-LeviM., GuellR., BarreiroE., et al. (2002). Inspiratory muscle training in patients with chronic obstructive pulmonary disease: structural adaptation and physiologic outcomes. Am J Respir Crit Care Med, 166, 1491–1497.
103.
ReuserA.J., KroosM.A., PonneN.J., WoltermanR.A., et al. (1984). Uptake and stability of human and bovine acid alpha-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients. Exp Cell Res, 155, 178–189.
104.
ReuserA.J., KroosM.A., HermansM.M., BijvoetA.G., et al. (1995). Glycogenosis type II (acid maltase deficiency). Muscle Nerve, 3, S61–S69.
105.
RomerL.M., and McconnellA.K. (2004). Inter-test reliability for non-invasive measures of respiratory muscle function in healthy humans. Eur J Appl Physiol, 91, 167–176.
106.
RutledgeE.A., HalbertC.L., and RussellD.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol, 72, 309–319.
107.
SamulskiR.J. (1993). Adeno-associated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev, 3, 74–80.
108.
SamulskiR.J., ChangL.S., and ShenkT. (1987). A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol, 61, 3096–3101.
109.
SidmanR.L., TaksirT., FidlerJ., ZhaoM., et al. (2008). Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol, 67, 803–818.
110.
SmithB.K., BleiweisM.S., ZauharJ., and MartinA.D. (2011). Inspiratory muscle training in a child with nemaline myopathy and organ transplantation. Pediatr Crit Care Med, 12, e94–98.
111.
SnyderR.O., MiaoC.H., PatijnG.A., SprattS.K., et al. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet, 16, 270–276.
112.
SongS., MorganM., EllisT., PoirierA., et al. (1998). Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci U S A, 95, 14384–14388.
113.
StubbingsA.K., MooreA.J., DusmetM., GoldstrawP., et al. (2008). Physiological properties of human diaphragm muscle fibres and the effect of chronic obstructive pulmonary disease. J Physiol, 586, 2637–2650.
114.
SummerfordC., and SamulskiR.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72, 1438–1445.
115.
SummerfordC., BartlettJ.S., and SamulskiR.J. (1999). AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med, 5, 78–82.
116.
Van den HoutJ.M., ReuserA.J., De KlerkJ.B., ArtsW.F., et al. (2001). Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis, 24, 266–274.
117.
Van der PloegA.T., KroosM., Van DongenJ.M., VisserW.J., et al. (1987). Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase. J Neurol Sci, 79, 327–336.
118.
Van der PloegA.T., BolhuisP.A., WoltermanR.A., VisserJ.W., et al. (1988a). Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells. J Neurol, 235, 392–396.
119.
Van der PloegA.T., LoonenM.C., BolhuisP.A., BuschH.M., et al. (1988b). Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle. Pediatr Res, 24, 90–94.
120.
Van der PloegA.T., Van Der KraaijA.M., WillemsenR., KroosM.A., et al. (1990). Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II. Pediatr Res, 28, 344–347.
121.
Van der PloegA.T., KroosM.A., WillemsenR., BronsN.H., et al. (1991). Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest, 87, 513–518.
122.
Van HeesH.W., DekhuijzenP.N., and HeunksL.M. (2009). Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 179, 41–47.
123.
Vincent-LacazeN., SnyderR.O., GluzmanR., BohlD., et al. (1999). Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol, 73, 1949–1955.
124.
WatsonJ.G., Gardner-MedwinD., GoldfinchM.E., and PearsonA.D. (1986). Bone marrow transplantation for glycogen storage disease type II (Pompe's disease). N Engl J Med, 314, 385.
125.
WeitzmanM.D., KyostioS.R., KotinR.M., and OwensR.A. (1994). Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A, 91, 5808–5812.
126.
WelvaartW.N., PaulM.A., KusterD.W., Van WieringenW., et al. (2011a). Gene expression profile in the diaphragm following contractile inactivity during thoracic surgery. Int J Physiol Pathophysiol Pharmacol, 3, 167–175.
127.
WelvaartW.N., PaulM.A., StienenG.J., Van HeesH.W., et al. (2011b). Selective diaphragm muscle weakness after contractile inactivity during thoracic surgery. Ann Surg, 254, 1044–1049.
128.
WijnhovenJ.H., JanssenA.J., Van KuppeveltT.H., RodenburgR.J., et al. (2006). Metabolic capacity of the diaphragm in patients with COPD. Respir Med, 100, 1064–1071.
129.
XiaoW., ChirmuleN., BertaS.C., McculloughB., et al. (1999). Gene therapy vectors based on adeno-associated virus type 1. J Virol, 73, 3994–4003.
130.
XiaoX., LiJ., and SamulskiR.J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol, 70, 8098–8108.
131.
XiaoX., LiJ., MccownT.J., and SamulskiR.J. (1997). Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol, 144, 113–124.
132.
XiaoX., LiJ., and SamulskiR.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 72, 2224–2232.
133.
ZaretskyJ.Z., CandottiF., BoerkoelC., AdamsE.M., et al. (1997). Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. Hum Gene Ther, 8, 1555–1563.
134.
ZolotukhinS., ByrneB.J., MasonE., ZolotukhinI., et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 6, 973–985.
135.
ZolotukhinS., PotterM., ZolotukhinI., SakaiY., et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods, 28, 158–167.
